Related Experiment Videos
Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3
Eviatar Fields1, Dean Elterman2, Naeem Bhojani3
1Faculty of Medicine, McGill University, Montreal, QC, Canada.
Introduction:
Benign prostatic hyperplasia (BPH) is among the most common conditions affecting aging men, with resulting lower urinary tract symptoms (LUTS) impeding on quality of life. While many medication classes exist for treatment of LUTS secondary to BPH, their increasing prevalence in a growing and aging population begs the need for novel therapeutic avenues.
Areas Covered:
This review covers the rationale for use of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists in LUTS secondary to BPH. We evaluate their efficacy, pharmacokinetics, and safety, as well as potential drug-drug interactions. Finally, we evaluate their use in combination with standard-of-care medications, as well as their use in vulnerable populations. Included studies in this literature review and expert opinion were found using PubMed.
Expert Opinion:
Mirabegron, vibegron, and tadalafil appear to be safe and efficacious medications in treatment of LUTS. Studies generally show favorable pharmacokinetics, and they can be used in combination with other BPH medications. Further studies are needed to understand the role of pharmacogenetics and use of these medications after surgical treatment. Thus, phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists are important tools in the urologist's toolbox for treatment of BPH.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:31Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers